Battipaglia Irma, O'Neill James, Hogarth Andrew J, Tayebjee Muzahir H
Irma Battipaglia, Department of Cardiovascular Diseases, Catholic University of the Sacred Heart "A. Gemelli" Hospital, 00168 Rome, Italy.
World J Cardiol. 2017 May 26;9(5):422-428. doi: 10.4330/wjc.v9.i5.422.
Ischaemic stroke is one of the commonest causes of morbidity and mortality worldwide and around a fifth of events can be attributed to a cardioembolic source. This is typically due to atrial fibrillation (AF), the most common sustained cardiac arrhythmia. However, AF can, at times, be difficult to detect due to a relative lack of symptoms and the fact that it can be paroxysmal in nature. Studies have shown that diagnosis of AF improves as the length of cardiac monitoring increases. However, prolonged cardiac monitoring is not a cost-effective way of diagnosing AF. Therefore, an alternative approach may be to empirically anticoagulate individuals who are at high risk of stroke. This article summarises current evidence surrounding stroke risk prediction, the use of anticoagulation in the secondary prevention of stroke and its use in the primary prevention of stroke in high risk groups with the aim of determining whether empirical anticoagulation is a safe and effective strategy.
缺血性中风是全球发病和死亡的最常见原因之一,约五分之一的病例可归因于心源性栓塞源。这通常是由于心房颤动(AF),最常见的持续性心律失常。然而,由于相对缺乏症状且其本质上可能是阵发性的,AF有时难以检测。研究表明,随着心脏监测时间的延长,AF的诊断率会提高。然而,延长心脏监测并不是诊断AF的一种具有成本效益的方法。因此,另一种方法可能是对中风高危个体进行经验性抗凝。本文总结了围绕中风风险预测、抗凝在中风二级预防中的应用以及在高危人群中风一级预防中的应用的当前证据,目的是确定经验性抗凝是否是一种安全有效的策略。